GP-100 antigen Completed Phase 2 Trials for Stage IIIB Intraocular Melanoma / Ciliary Body and Choroid Melanoma, Small Size / Mucosal Melanoma / Iris Melanoma / Extraocular Extension Melanoma / Stage IIIc Melanoma / Stage IIIC Intraocular Melanoma / Stage IV Melanoma / Stage IIIB Melanoma / Recurrent Melanoma / Recurrent Intraocular Melanoma / Stage IV Intraocular Melanoma / Ciliary Body and Choroid Melanoma, Medium/Large Size / Stage IIIA Intraocular Melanoma / Stage IIIA Melanoma / Metastatic Intraocular Melanoma / Stage IIC Melanoma Treatment

Indications	Status	Purpose	Phase
DBCOND0030839 (Stage IIIB Intraocular Melanoma) DBCOND0030836 (Ciliary Body and Choroid Melanoma, Small Size) DBCOND0030701 (Mucosal Melanoma) DBCOND0030826 (Iris Melanoma) DBCOND0029487 (Extraocular Extension Melanoma) DBCOND0052015 (Stage IIIc Melanoma) DBCOND0030840 (Stage IIIC Intraocular Melanoma) DBCOND0028660 (Stage IV Melanoma) DBCOND0028890 (Stage IIIB Melanoma) DBCOND0028662 (Recurrent Melanoma) DBCOND0029488 (Recurrent Intraocular Melanoma) DBCOND0030841 (Stage IV Intraocular Melanoma) DBCOND0030825 (Ciliary Body and Choroid Melanoma, Medium/Large Size) DBCOND0030838 (Stage IIIA Intraocular Melanoma) DBCOND0028889 (Stage IIIA Melanoma) DBCOND0030837 (Metastatic Intraocular Melanoma) DBCOND0028888 (Stage IIC Melanoma)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT00085189	Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma	Agatolimod (DB15018) GP-100 antigen (DB14800) Incomplete Freund's adjuvant (DB17475) Tyrosinase (DB16626)